Compare Colgate-Palmolive Company (CL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Citius Pharmaceuticals Inc — how do they compare? Colgate-Palmolive Company trades at $92.22 (market cap $74.26B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Colgate-Palmolive Company is far larger — about 3964.8× Citius Pharmaceuticals Inc's market cap, and Colgate-Palmolive Company pays a 2.28% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CL | CTXR | |
|---|---|---|
Market Cap | $74.26B | $18.73M |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $1.82 |
52-Week Low | $74.98 | $0.48 |
Enterprise Value | $80.74B | $14.95M |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.27, up 0.29% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.99, exceeding estimates, driven by strong margins and organic growth in emerging markets, though North American performance remains weak. Operating cash flow remains robust at $4.2 billion in 2025, supporting shareholder returns.
Outlook is mixed: valuation appears stretched with a P/E of 36.72, but analyst consensus targets $99.10. Risks include competitive pressures in North America and high debt levels. The stock offers a stable dividend, but growth concerns and insider selling warrant caution.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
